Advocacy
CHADD is part of a social movement that seeks to shape the conversation on how society treats, accommodates, and views people affected by ADHD. Our movement is made up of countless people affected by ADHD, their families, teachers, friends, and leaders in the fields of ADHD research, education, and mental health. We realize the most effective way to accomplish our goals is through sustained and strategic outreach to policymakers on the state and federal levels.
We are making a difference for for families and adults affected ADHD. And we need your help! We want you to be equipped with information to make a difference in your own life, whether that means dealing with issues in the classroom, the boardroom, or your living room.
CURRENT ISSUES
The US Food and Drug Administration recently asked for comments on making stimulant medications more difficult to abuse and how those changes could affect the millions of people who include medication in their ADHD treatment plans. The Federal Register notice states that stimulant medications can be open to abuse but that reformulating them can potentially…
At eight years old, Michael was diagnosed with ADHD. The traditional city school he attended declined to evaluate him to determine eligibility for special education and related services because his grades were above average. Instead, the school provided Michael with minimal accommodations through a 504 plan. As the years progressed, Michael’s grades began to decline,…
CHADD and Russell A. Barkley, Ph.D., Partner Announce New Findings Lanham, Md. (Jan. 8, 2019)— The message is clear. Treatment for attention-deficit/hyperactivity disorder (ADHD), along with the related health risks it poses, has the possibility of adding an average of nine to 13 years to the lifespan of children and adults diagnosed with ADHD.…
CHADD has become aware of state and local policies, including legislation and regulations, intended to address the misuse of opioids, but which may have unintended consequences for children and adults prescribed FDA-approved medications to treat attention deficit hyperactivity disorder (ADHD). Read the full statement.
- « Previous
- 1
- 2
- 3
- 4
- Next »
RESOURCES
Developing Diagnosis and Treatment of Adult ADHD Guidelines: DaTAA Project
In 2022, CHADD received funds from a generous donor to sponsor and support the development of national guidelines in the U.S. for the diagnosis and treatment of adult ADHD. This milestone has been achieved due to the sustained efforts of our Public Policy Committee and builds on the committee’s published recommendations emerging from a national CHADD summit held in 2019 (see “The Adverse Health Outcomes, Economic Burden, and Public Health Implications of Unmanaged ADHD,” Journal of Attention Disorders, 2022 Apr;26(6):807-808). The group has been named the “DATAA Project” (Diagnosis and Treatment of Adult ADHD) and consists of a coalition of organizations focused on this goal, including the American Psychiatric Association, The American Psychological Association, The American Academy of Neurology, The American Association of Nurse Practitioners, and The National Alliance on Mental Illness. In 2023, CHADD signed an agreement to coordinate efforts on the project with The American Professional Society of ADHD and Related Disorders (APSARD). Working together with APSARD, the coalition expects to launch guidelines in 2025 and develop resources and toolkits for providers across the U.S. to implement these new diagnostic and treatment guidelines.
WHITE PAPER
Proceedings of the ADHD Public Health Summit
Washington, DC
October 7, 2019
Presented by Children and Adults with Attention-Deficit/ Hyperactivity Disorder (CHADD)
TOOLKITS
CHADD Advocacy ManualADVOCACY PARTNERS
- CDC-National Center Birth Defects & Developmental Disabilities External Partners Group
- Consortium for Citizens with Disabilities
- Mental Health Liaison Group
- IDEA Partnership
- Bazelon Center for Mental Health Law
- Alliance to Prevent Restraint, Aversive Intervention & Seclusion
- American Academy of Child and Adolescent Psychiatry
- National Alliance on Mental Illness
- Mental Health America